FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileStarling Oncology, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
STLN
Starling Oncology, Inc. Stock AnalysisComprehensive stock analysis for Starling Oncology, Inc. (STLN) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisSTLN
STLN
Starling Oncology, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
STLN
  1. Home
  2. Stocks
  3. Starling Oncology, Inc.
ST

Starling Oncology, Inc.

🇺🇸STLN•NASDAQ
ST

Starling Oncology, Inc.

🇺🇸STLN•NASDAQ
Market cap
$305.97M

Your view on STLN

Mkt Cap
$305.97M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Starling Oncology, Inc.

Industry
Medical - Care Facilities
Sector
Healthcare
CEO
Not available
Headquarters
18000 Studebaker Road, Suite 800, Cerritos, CA, US
Industry
Medical - Care Facilities
Sector
Healthcare
CEO
Not available
Headquarters
18000 Studebaker Road, Suite 800, Cerritos, CA, US
Description

Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population.

It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Starling Oncology, Inc.. Starting points for Starling Oncology, Inc.: EPS -$0.34, beta 0.42 — an Medical - Care Facilities name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Starling Oncology, Inc.. Trailing twelve-month EPS for Starling Oncology, Inc. stands at -$0.34. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
Analysts' target$9.00average of analysts' targets
Current price—

Buy

Targets, low to high

$9.00

Low $9.00

Middle $9.00

High $9.00

Analyst ratings

4 firms, last 12 months
  • Strong Buy0
  • Buy4
  • Hold0
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterSep 2024Next quarterDec 2024This yearYear to Dec 2024Next yearYear to Dec 2025
Average estimate−$0.07−$0.08−$0.36−$0.59
Lowest estimate−$0.07−$0.08−$0.36−$0.59
Highest estimate−$0.07−$0.08−$0.36−$0.58
Number of analysts1111
A year ago————
Growth vs a year ago————

Revenue estimates

TotalThis quarterSep 2024Next quarterDec 2024This yearYear to Dec 2024Next yearYear to Dec 2025
Average estimate$107.54M$109.15M$414.70M$500.58M
Lowest estimate$106.31M$108.04M$412.42M$497.83M
Highest estimate$108.74M$111.00M$417.59M$504.06M
Number of analysts1111
A year ago————
Growth vs a year ago————
Recent rating and target changes (12)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Starling Oncology, Inc.. Starling Oncology, Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold STLN12 companies · 8 funds
More Medical - Care Facilities companies
TickerTypeCompanySectorExchangeMkt cap
EXE.TOExtendicare Inc.HealthcareTSX$2.7B
EXETFExtendicare Inc.HealthcareOTC$1.7B
FCGDFirst Colombia Gold Corp.HealthcareOTC$483,789
FCHSFirst Choice Healthcare Solutions, Inc.HealthcareOTC$131,833
FMCQFFresenius Medical Care AG & Co. KGaAHealthcareOTC$14.3B
FMSFresenius Medical Care AG & Co. KGaAHealthcareNYSE$11.0B
FOXOFOXO Technologies Inc.HealthcareOTC$8,997
FPCGFirst Physicians Capital Group, Inc.HealthcareOTC$10.1M
FSNUFFresenius SE & Co. KGaAHealthcareOTC$31.5B
FSNUYFresenius SE & Co. KGaAHealthcareOTC$136.1B
GBCSSelectis Health, Inc.HealthcareOTC$9.8M
GLH.AXGlobal Health LimitedHealthcareASX—
ETFs holding Starling Oncology, Inc.
TickerFundFund assets% of the fund
IWMiShares Russell 2000 ETF$76.6B in assets0.01%
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
VXFVanguard Extended Market ETF$30.2B in assets0.01%
IWOiShares Russell 2000 Growth ETF$13.7B in assets0.01%
VMO.TOVanguard Global Momentum Factor ETF$477M in assets0.05%
VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.03%
RSSLGlobal X - Russell 2000 ETF$1.4B in assets0.01%
VHTVanguard Health Care ETF$19.1B in assets0.01%

Largest holders first, then the funds most concentrated in STLN.

Ownership & News

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Starling Oncology, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming Starling Oncology, Inc.. Starling Oncology, Inc. is a $306.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Starling Oncology, Inc.. Coverage tracks Starling Oncology, Inc. within Medical - Care Facilities (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Starling Oncology, Inc.

STLN AnalysisWeak
Past
1
Growth
2
Health
1
Profit
1
Value
1